125 Views

VC-backed Versartis raises $126 mln for IPO

Versartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “VSAR.” Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.

112 Views

VC-backed Agile Therapeutics files for IPO

Agile Therapeutics has filed for an IPO. The number of shares that will be offered as well as the pricing terms of the stock have yet to be set. RBC Capital Markets and William Blair & Company will serve as the lead underwriters. Based in Princeton, NJ, Agile Therapeutics is a women’s health specialty pharmaceutical company focused on developing prescription contraceptives. Its backers include Aisling Capital, Care Capital, Investor Growth Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital.

ViewRay Raises Fresh $15M for Its Medical Imaging Technology

ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company’s machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay’s investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.

Versartis Closes Series C Financing

Versartis, an emerging biotechnology company has completed a $25 million Series C financing lead by new investor Aisling Capital. Also participating in the round were existing investors Index Ventures, New Leaf Venture Partners and Advent Venture PartnersAdvent Life Sciences fund.

Phizer Buys VC-Backed NextWave Pharmaceuticals

Phizer is snapping up NextWave Pharmaceuticals—a company backed by a laundry list of investors including Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures. Under the terms of the deal, Pfizer will pay $255 million to NextWave’s shareholders at closing. NextWave’s shareholders are eligible to receive up to $425 million in additional money, based on sales milestones. NextWave closed a $45 million round last January.

AxioMed Closes Series D Financing

AxioMed Spine Corporation, a spinal orthopedics company has closed its Series D financing, raising $5 million in two tranches from current and new investors. This funding boosts the previously announced $15 million Series D financing. Investors in the business include Siemens Venture Capital, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors. PRESS RELEASE […]

TransEnterix Closes $15 million Round

TransEnterix Inc. has closed a $15 million in venture capital financing. TransEnterix currently markets throughout Europe and the US a platform called the SPIDER® Surgical System. The funding is the second tranche of the company’s Series B financing secured in 2009. Aisling Capital, Quaker BioVentures, Intersouth Partners, Synergy Life Science Partners and SV Life Sciences […]

T2 Biosystems Seals $23M Series D

Lexington, Mass.-based T2 Biosystems has closed a $23 million Series D financing round led by new investor Aisling Capital. Return backers Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, Physic Ventures, Partners Healthcare, Arcus Ventures, RA Capital, Camros Capital and WS Investments also contributed. The money will help with ongoing development and clinical trials of the company’s diagnostic technology.

PEHUB Community

Join the 12494 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups